A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Summary

This is a research study of a radiation treatment called stereotactic body radiotherapy (SBRT) plus a medicine called sorafenib. The purpose of this study is to evaluate the safety of SBRT plus Sorafenib to see what effects (good and bad) it has on the treatment of liver cancer.

Timeline

Start

2012-02

Primary completion

2014-08

Completion

2014-10

Outcome

Outcome not reported

Stopped (Enrollment): “Trial had no patients accrued while open”

Drugs

Indications